by Richard Daverman, PhD
July 25, 2012 -- Suzhou Connect Biopharmaceuticals, Ltd. gained control of two series of anti-inflammatory compounds from Arena Pharma of San Diego. Zheng Wei, PhD, initiated development of the compounds while he was Director of Immunology at Arena, and he is now Co-founder and CEO of Suzhou Connect. Terms of the agreement were not disclosed. More details....
Stock Symbol: (NSDQ: ARNA)
